Auto-generated from public data. Not the firm's stated position.
KIZOO Technology Capital appears to focus on late-stage biotech investments, particularly in cellular and regenerative medicine applications, with a recent portfolio suggesting concentration in longevity and mitochondrial health therapeutics. Based on disclosed data, the firm targets series-C and growth-stage companies with check sizes around €3.0M, positioning itself within the European deep-tech biotech investment landscape.
Generated 8 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.